A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Macular Edema Secondary to Inflammation

In brief

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)

Key facts

Study ID
NCT06990399
Run by
Kodiak Sciences Inc
People needed
600
Starts
2025-07-30
Expected to finish
2027-11-01
Last updated by the study team
2026-05-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.